Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL

Pirker, Robert; Hedenus, Michael; Vansteenkiste, Johan; Hernandez, Enrique; Belton, Laura; Terwey, Jan-Henrik

doi:10.1016/j.clinthera.2015.11.012

Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL

Author:

Pirker, Robert

Hedenus, Michael ; Vansteenkiste, Johan ; Hernandez, Enrique ; Belton, Laura ; Terwey, Jan-Henrik

Keywords:

Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, chemotherapy-induced anemia, darbepoetin alfa, hemoglobin, licensed indication, meta-analysis, transfusion, ERYTHROPOIESIS-STIMULATING AGENTS, EVERY 3 WEEKS, LUNG-CANCER PATIENTS, WEEKLY EPOETIN-ALPHA, DOUBLE-BLIND, STUDY-LEVEL, LYMPHOPROLIFERATIVE MALIGNANCIES, RECEIVING CHEMOTHERAPY, INTRAVENOUS IRON, CONTROLLED-TRIAL, Aged, Anemia, Antineoplastic Agents, Blood Transfusion, Darbepoetin alfa, Databases, Factual, Female, Hematinics, Hemoglobins, Humans, Lung Neoplasms, Lymphoproliferative Disorders, Male, Middle Aged, Placebos, Randomized Controlled Trials as Topic, Time Factors, 1115 Pharmacology and Pharmaceutical Sciences, Optoelectronics & Photonics, 3202 Clinical sciences, 3214 Pharmacology and pharmaceutical sciences

Abstract:

Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemoglobin (Hb) and transfusion outcomes when initiated at Hb ≤10 g/dL (the threshold specified in the summary of prescribing characteristics). We assessed DA, initiated according to current labeling (Hb ≤10 g/dL), in chemotherapy-induced anemia (CIA).